Cytokinetics shares new non‑obstructive HCM data and aims to file supplemental NDA this quarter
Cytokinetics presented additional results from its ACACIA‑HCM trial at the HFSA Annual Scientific Meeting, showing aficamten improved global exercise performance and clinical response in non‑obstructive hypertrophic cardiomyopathy patients. Serious heart‑failure events occurred in 4.7% of aficamten‑treated patients versus 1.2% on placebo. The company intends to file a supplemental New Drug Application with the FDA within the next three months.
Why it matters
The company says the data support filing a supplemental NDA this quarter, which could expand the approved indication for aficamten and affect CYTK’s valuation. Analysts will watch the regulatory timeline for potential market impact.
Key facts
- 1Serious heart‑failure events were reported in 4.7% of aficamten patients compared with 1.2% of placebo patients. stocktitan.net
- 2At 36 weeks, aficamten significantly improved the Boston Exercise Aggregate Physiologic Response Score versus placebo (p<0.001). globenewswire.com
- 353% of aficamten‑treated patients showed a response in at least three of five clinical domains versus 13% of placebo patients. rttnews.com
- 4At the end of titration, 80.7% of patients were on a 15 mg or 20 mg dose. globenewswire.com
Open questions
- Material 3 states that LVEF < 50% occurred in 27 patients (10.5%) on aficamten and 2 patients (0.8%) on placebo, while material 5 reports LVEF < 50% in 10% of aficamten patients and 1% of placebo patients.
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.